Cefotan
(Cefotetan)Phase 2Small molecule
Cefotan is one of 5 small molecule programs targeting Escherichia coli Infections. It is currently in Phase 2.
1
Indications
3
Total Trials
1
Active Trials
4
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in Escherichia Coli Infections
#DrugCompanyPhaseTrials
1Levaquin
WWim Janssens
Approved
Fluzone
SanofiPhase 3
Cefotan
BB. Braun Medical Inc.
Phase 2
Beta Lactam Antibiotics
OOregon Health and Science University
Phase 2
Carbapenems
OOregon Health and Science University
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Laparoscopic Cholecystectomy1 trial
Effectiveness of Prophylactic Antibiotics Therapy in Laparoscopic Cholecystectomy on Infection Rate
Completed·—·Phase 1·NCT04726046·529 enrolled
Safety and Efficacy1 trial
Regulatory
FDA Approval Timeline[4]
Dec 27, 1985
CEFOTAN
NDA NDA050588
Jul 30, 1993
CEFOTAN IN PLASTIC CONTAINER
NDA NDA050694
Aug 9, 2007
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER
NDA NDA065430
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cefotetan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- BB. Braun Medical Inc.